Working… Menu
Trial record 1 of 1 for:    ICP-CL-00107
Previous Study | Return to List | Next Study

A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04014205
Recruitment Status : Recruiting
First Posted : July 10, 2019
Last Update Posted : December 23, 2020
Information provided by (Responsible Party):
Beijing InnoCare Pharma Tech Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 17, 2021
Estimated Study Completion Date : July 3, 2023